Clinical Competition Candidate
XELPROS
XELPROS carries product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 38 months away. Active clinical competition may compress the generic entry window.
LOE window
38months
to latest listed patent expiry (September 12, 2029)
Expiry attractiveness: 4/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 288
Phase 2/3 trials: 119
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: LATANOPROST
Applicant (NDA holder): SUN PHARMACEUTICAL INDUSTRIES LTD
Confidence: High